Navigation Links
WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
Date:2/12/2008

NORTH BRUNSWICK, N.J., Feb. 12 /PRNewswire/ -- WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop food ingredients for wellness products, today announced the appointment of Robert M. Hellauer as Chief Financial Officer.

Mr. Hellauer, 56, comes to WellGen with over thirty years of broad financial leadership in the pharmaceutical, consumer and telecommunications industries. Prior to joining WellGen, he spent six years in private equity and venture-backed environments. Mr. Hellauer's earlier experience includes senior positions at Lucent Technologies / AT&T, General Signal Corporation, and Johnson & Johnson.

Dr. Kathleen Mullinix, Chief Executive Officer of WellGen, said, "Bob joins WellGen at a strategically important period, as we emerge from our origins as a research boutique and gain traction as a commercial entity. The role of Chief Financial Officer will be critical to ensuring a successful, sustainable business as we roll out our first functional food ingredient to the marketplace and significantly expand the number of ingredients in our pipeline."

Mr. Hellauer graduated from the University of Pennsylvania, where he received a Bachelor of Science degree and a Master of Business Administration degree from The Wharton School.

About WellGen

WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for the food, therapeutics, and dietary supplement markets, with a strategic focus on functional foods. WellGen's proprietary technology platform is a method of screening the effects of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases. Please visit our website at http://www.wellgen.com for more information.


'/>"/>
SOURCE WellGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. WellGen, Inc. Names Nancy E. Rawson, Ph.D., Chief Scientific Officer
2. Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
3. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
6. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
7. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
8. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
9. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
10. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
11. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Regular discussions on a range of subjects including policies, debt ... said Poloz. Speaking at a lecture to the ... pointed to the country,s inflation target, which is set by ... "In certain areas there needs to ... goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):